Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CLRB Cellectar Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: CLRB
Price (delayed)
$0.245
Market cap
$11.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.55
Enterprise value
-$2.14M
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations.
Highlights
The company's EPS has surged by 85% YoY and by 55% QoQ
Cellectar Biosciences's net income has surged by 61% YoY and by 45% QoQ
CLRB's quick ratio has soared by 65% YoY but it is down by 7% from the previous quarter
The equity has contracted by 42% from the previous quarter and by 34% YoY
Key stats
What are the main financial stats of CLRB
Market
Valuations
Earnings
Shares outstanding
46.08M
Market cap
$11.29M
Enterprise value
-$2.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.37
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$46.18M
Net income
-$24.54M
EBIT
-$24.48M
EBITDA
-$24.22M
Free cash flow
-$43.69M
Per share
Balance sheet
Liquidity
EPS
-$0.55
EPS diluted
-$0.73
Free cash flow per share
-$0.95
Book value per share
$0.18
Revenue per share
$0
TBVPS
$0.35
Total assets
$16.04M
Total liabilities
$6.41M
Debt
$474,349
Equity
$8.25M
Working capital
$8.87M
Debt to equity
0.06
Current ratio
2.47
Quick ratio
2.31
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-90.7%
Return on equity
-196%
Return on invested capital
N/A
Return on capital employed
-244.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLRB stock price
How has the Cellectar Biosciences stock price performed over time
Intraday
-3.43%
1 week
-0.97%
1 month
-13.49%
1 year
-92.64%
YTD
-18.06%
QTD
-22.3%
Financial performance
How have Cellectar Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$46.18M
Net income
-$24.54M
Gross margin
N/A
Net margin
N/A
Cellectar Biosciences's net income has surged by 61% YoY and by 45% QoQ
Cellectar Biosciences's operating income has increased by 11% from the previous quarter but it has decreased by 9% YoY
Price vs fundamentals
How does CLRB's price correlate with its fundamentals
Growth
What is Cellectar Biosciences's growth rate over time
Valuation
What is Cellectar Biosciences stock price valuation
P/E
N/A
P/B
1.37
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 85% YoY and by 55% QoQ
The price to book (P/B) is 63% lower than the last 4 quarters average of 3.7 and 45% lower than the 5-year quarterly average of 2.5
The equity has contracted by 42% from the previous quarter and by 34% YoY
Efficiency
How efficient is Cellectar Biosciences business performance
The company's return on assets has surged by 70% YoY and by 31% QoQ
The company's return on equity rose by 40% QoQ
Dividends
What is CLRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLRB.
Financial health
How did Cellectar Biosciences financials performed over time
The total assets is 150% more than the total liabilities
The total liabilities has plunged by 78% YoY and by 35% from the previous quarter
Cellectar Biosciences's current ratio has soared by 70% YoY but it has decreased by 4.3% from the previous quarter
The company's debt is 94% lower than its equity
The company's debt to equity has surged by 100% QoQ and by 50% YoY
The equity has contracted by 42% from the previous quarter and by 34% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.